NCT02295865 / 2015-000277-12: A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis |
|
|
| Completed | 2 | 62 | US, Europe | JNJ-38518168 60 mg, Toreforant, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo | Janssen Research & Development, LLC | Psoriasis | 03/16 | 03/16 | | |
